By Gabriel Paijo 
In a landmark advancement for the field of synthetic biology, researchers at Columbia Engineering have unveiled a sophisticated cancer treatment platform that orchestrates a unique cooperation between bacteria and viruses. The study, recently published in the journal Nature Biomedical Engineering, details the development of a system called CAPPSID—short for Coordinated Activity of Prokaryote and Picornavirus for Safe Intracellular Delivery. By engineering a "Trojan horse" mechanism, the team has successfully demonstrated a method to shield therapeutic viruses within tumor-seeking bacteria, allowing them to bypass the host’s immune system and deliver a potent anti-cancer payload directly into the heart of malignant growths.
The research was spearheaded by the Synthetic Biological Systems Lab at Columbia University, led by Tal Danino, an associate professor of biomedical engineering. The project represents a high-level collaboration with Charles M. Rice, a Nobel laureate and virology expert at The Rockefeller University. By bridging the disparate worlds of bacteriology and virology, the team has created what they describe as their most technically advanced platform to date, offering a potential solution to some of the most persistent hurdles in modern oncology.
The Dual-Microbe Strategy: Engineering a Synthetic Partnership
For decades, scientists have explored the use of individual microbes—either bacteria or viruses—to combat cancer. Oncolytic viruses are designed to infect and lyse cancer cells, while certain bacterial strains, such as Salmonella typhimurium, have a natural affinity for the nutrient-rich, low-oxygen environments found inside solid tumors. However, both approaches face significant limitations when used in isolation.
Viruses are often neutralized by the patient’s immune system before they can reach the tumor site, especially if the patient has had prior exposure or vaccination. Conversely, while bacteria are excellent at homing in on tumors, they often struggle to penetrate deep into the cellular architecture or achieve the same level of rapid cytotoxicity as a virus.
The CAPPSID system overcomes these limitations by combining the strengths of both organisms. "We aimed to enhance bacterial cancer therapy by enabling the bacteria to deliver and activate a therapeutic virus directly inside tumor cells," explained co-lead author Jonathan Pabón, an MD/PhD candidate at Columbia. This multi-organism approach allows the bacteria to act as a transport vehicle, protecting the viral "passengers" from circulating antibodies until they reach the safety of the tumor microenvironment.
Overcoming the Immunological Barrier: The Bacterial Invisibility Cloak
One of the primary challenges in viral therapy is the presence of neutralizing antibodies. In a clinical setting, a patient’s immune system is primed to identify and destroy foreign viral particles. If a patient has previously encountered a similar virus, their immune memory will trigger a rapid response, rendering the treatment ineffective before it ever encounters a cancer cell.
The Columbia team addressed this by "tucking" the viral genetic material inside the bacteria. Because the bacteria are larger and possess their own mechanisms for evading certain immune responses, they serve as an "invisibility cloak." This allows the virus to circulate through the bloodstream undetected by the host’s antibodies.
"The bacteria act as an invisibility cloak, hiding the virus from circulating antibodies, and ferrying the virus to where it is needed," said Zakary S. Singer, a co-lead author and former postdoctoral researcher in the Danino lab. This strategy is particularly vital for viruses derived from common families, such as picornaviruses, to which much of the human population has already been exposed. By utilizing bacteria as a delivery vehicle, the researchers have opened the door for using highly effective oncolytic viruses in patients who would otherwise be immune to them.
Targeting the Tumor Microenvironment: The Role of Salmonella Typhimurium
The bacterial component of the CAPPSID system utilizes a modified strain of Salmonella typhimurium. This specific bacterium is well-known in cancer research for its "tumor-homing" capabilities. Unlike healthy tissue, the interior of a solid tumor is often necrotic and hypoxic (low in oxygen), providing a niche environment where Salmonella can thrive.
Once the bacteria migrate to the tumor and penetrate the cancer cells, the CAPPSID system triggers a programmed release. The researchers engineered the bacteria to undergo lysis—a process where the bacterial cell wall breaks down—once they are inside the cancerous cells. This release dumps the viral RNA directly into the cytoplasm of the cancer cell.
This intracellular release ensures that the virus begins its replication cycle in the very heart of the tumor. As the virus replicates, it causes the cancer cell to burst, releasing more viral particles to infect neighboring malignant cells. This creates a self-sustaining cycle of destruction within the tumor while the bacteria continue to colonize the area and provide fresh "shipments" of the viral genome.
Synthetic Safeguards: Preventing Runaway Infections
A recurring concern in live-microbe therapies is the risk of systemic infection or the spread of the virus to healthy organs. To mitigate this, the Columbia and Rockefeller team implemented a sophisticated molecular fail-safe. They engineered a "synthetic dependence" between the two organisms.
The virus used in the CAPPSID system was modified so that it cannot form functional, spreadable particles without a specific enzyme called a protease. Crucially, the virus does not carry the gene for this protease itself; instead, the gene is placed within the bacteria.
"Spreadable viral particles could only form in the vicinity of bacteria, which are needed to provide special machinery essential for viral maturation," Singer noted. Because the bacteria are programmed to only survive and thrive within the specific environment of the tumor, the protease is unavailable in healthy tissues. If a viral particle were to escape the tumor and enter a healthy organ, it would find itself without the bacterial "machinery" required to replicate and spread. This dual-layer control system ensures that the therapy remains localized, significantly reducing the potential for off-target effects.
Validating the Technology: Results from Mouse Models
The efficacy of the CAPPSID platform was validated through a series of experiments in mouse models of cancer. The researchers observed that the coordinated bacteria-virus system was significantly more effective at reducing tumor volume than either the bacteria or the virus administered alone.
Data from the study indicated that the CAPPSID-treated mice showed higher rates of tumor regression and improved survival outcomes. Furthermore, the researchers confirmed that the virus remained localized within the tumor tissue, with no significant viral load detected in the lungs, liver, or spleen of the test subjects. This confirmed the effectiveness of the protease-dependent safety mechanism.
The study also highlighted the system’s ability to penetrate dense solid tumors, which are often resistant to traditional chemotherapy and immunotherapy due to high interstitial pressure and poor vascularization. The "homing" instinct of the Salmonella allowed the therapy to reach the deep, necrotic core of the tumors that are typically inaccessible to other drugs.
Future Horizons and Clinical Translation
With the successful validation of the CAPPSID system in laboratory models, the research team is now focused on the path toward human clinical trials. Danino, Rice, Singer, and Pabón have already filed a patent application (WO2024254419A2) related to the technology, signaling a clear intent to commercialize and translate the findings into a viable medical product.
"As a physician-scientist, my goal is to bring living medicines into the clinic," Pabón said. "Efforts toward clinical translation are currently underway to translate our technology out of the lab."
The team is currently developing a "toolkit" of viral and bacterial components. By swapping out different types of viruses or payloads, they hope to tailor the CAPPSID system to treat various forms of cancer, including those that are currently considered "cold" or non-responsive to immunotherapy. Future research will also evaluate the compatibility of this system with bacterial strains that have already passed safety benchmarks in previous human clinical trials, potentially accelerating the regulatory approval process.
Implications for the Field of Synthetic Biology
The development of CAPPSID marks a shift in how scientists approach "living medicines." Rather than focusing on a single organism, the research suggests that the future of biotherapeutics may lie in multi-organism consortia. By engineering cooperation between different kingdoms of life—in this case, prokaryotes (bacteria) and viruses—researchers can create systems with "emergent properties" that exceed the capabilities of their individual parts.
This study also underscores the growing importance of "synthetic virology," a field that seeks to redesign viruses for beneficial purposes. By integrating these engineered viruses with bacterial delivery systems, the Columbia Engineering team has provided a blueprint for a new generation of smart, targeted, and safe cancer therapies.
As the medical community continues to seek alternatives to systemic chemotherapy and its associated side effects, platforms like CAPPSID offer a glimpse into a future where "living machines" are deployed with surgical precision to eliminate disease from within. The integration of homing mechanisms, immunological shielding, and molecular kill-switches represents a significant leap forward in the quest for a more effective and less toxic cure for cancer.
